Wednesday, November 13, 2013

Lapatinib May Fight TNBC

Lapatinib, which has been approved for use on Her2-positive tumors,  is also effective against triple-negative breast cancer in lab tests on mice, according to research published in Breast Cancer Research November 12, 2013.  Lapatinib  targets EGFR and  and  p65, which are present in both HER2-positive and triple-negative breast cancer cells.  Specifically, it is effective against the NF-κpathway that scientists believe may be a key regulator of TNBC.  Researchers suggest it should be used in combination with a proteasome inhibitor.  The study also demonstrated that lapatinib worked better than gefitinib and erlotinib, which are  specific EGFR inhibitors. 
In previous researchlapatinib, in combination with Herceptin, was effective against TNBC.

• Read more about TNBC in my book, Surviving Triple-Negative Breast Cancer.

• Please consider a donation to Positives About Negative to keep this site going.  This work is entirely supported by readers.  Just click on the Donate button in the right of the page.  Thank you!

No comments: